EP2873664A1 - Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof - Google Patents

Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof Download PDF

Info

Publication number
EP2873664A1
EP2873664A1 EP20130817593 EP13817593A EP2873664A1 EP 2873664 A1 EP2873664 A1 EP 2873664A1 EP 20130817593 EP20130817593 EP 20130817593 EP 13817593 A EP13817593 A EP 13817593A EP 2873664 A1 EP2873664 A1 EP 2873664A1
Authority
EP
European Patent Office
Prior art keywords
crystal
dimaleate
phenylamino
pyridin
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20130817593
Other languages
German (de)
French (fr)
Other versions
EP2873664A4 (en
EP2873664B1 (en
Inventor
Piaoyang Sun
Guaili Wu
Bo Yuan
Yongjiang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to PL13817593T priority Critical patent/PL2873664T3/en
Publication of EP2873664A1 publication Critical patent/EP2873664A1/en
Publication of EP2873664A4 publication Critical patent/EP2873664A4/en
Application granted granted Critical
Publication of EP2873664B1 publication Critical patent/EP2873664B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a crystalline form of dimaleate of tyrosine kinase inhibitors, particularly relates to form I crystal of (R, E)-N-(4-(3-chloro-4-(pyridin-2-yl-methoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6 -yl)-3-(1-methylpyrrolidino-2-yl)acrylamide dimaleate and the preparation and use thereof.
  • Receptor tyrosine kinase is a kind of transmembrane protein involved in signal transduction. It is shown that over 50% of the proto-oncogene and oncogene product have the tyrosine kinase activity, whose abnormal expression will cause tumorigenesis. Tyrosine kinase inhibitor has been approved to be on the market since 2001, which has become a new class of anticancer drugs with outperformance.
  • Epidermal growth factor receptor is a member of the receptor tyrosine kinase family.
  • the epidermal growth factor receptor pathway plays a very important role in the tumorigenesis and progression, which has become the main research subject and one of the developing targets in the field of cancer therapy.
  • drugs which has been on the market now comprise erlotinib, gefitinib and lapatinib (Tykerb, GW572016), as well as neratinib which is in the clinical phase now.
  • Patent WO2011029265 discloses the method for the preparation of the compound (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquino line-6-yl)-3-(1-methylpyrrolidino-2-yl)acrylamide (referred as SHR1258 below for convenience).
  • SHR1258 the compound
  • This drug molecule has distinct advantage of pharmacokinetics and pharmacodynamics.
  • patent WO2011029265 discloses the chemical structure and preparation method of compound SHR1258, but is silent to the condition of its salification.
  • SHR1258 dimaleate the dimaleate of this compound (referred as SHR1258 dimaleate below) has been described, and its structure is as follows:
  • the inventors did not make further research for the polymorph and preparation method of SHR1258 dimaleate.
  • the polymorph structure of the pharmaceutically active ingredient always affects the chemical stability of the drug. Different storage conditions and crystallization conditions may lead to the change in the polymorph structure of the compound, which is sometimes accompanied with other forms of polymorph.
  • amorphous drug product does not have regular crystal structure, which often has other defects such as poor product stability, smaller particle size, hard filtration, agglomerate easily, and poor liquidity. Thus, it is necessary to improve all aspects of the nature of the above product. It is need to search a new polymorph which has higher polymorph purity and better chemical stability.
  • the present invention is to provide a stable crystal form of SHR1258 dimaleate and the preparation method thereof.
  • the inventor has test a series of crystallization products of SHR1258 dimaleate obtained under various conditions by X-ray diffraction and DSC test. The results prove that a stable crystal form of SHR1258 dimaleate which is referred as form I crystal can be obtained under normal crystallization condition. DSC patterns of the present form I crystal of SHR1258 dimaleate show distinct fusion absorption peak at 130°C.
  • the X-ray diffraction pattern is shown in figure 1 which use Cu-K ⁇ radiation to obtain the X-ray diffraction patterns represented by 2 ⁇ angels and interplannar crystal spacing (d value) in which there are characteristic peaks at 6.28(14.06), 6.74(13.10), 10.60(8.34), 11.58(7.64), 13.50(6.55), 14.90(5.94),15.80(5.60), 18.26(4.85), 20.66(4.30), 21.14(4.20), 22.96(3.87), 24.34(3.65), 25.54(3.49), 26.12(3.41).
  • d value interplannar crystal spacing
  • the method for the preparation of form I crystal of SHR1258 dimaleate of the present invention comprises the following steps:
  • the polar organic solvent with fewer carbon atom and higher volatility which could be used as crystallization solvent is preferred, such as alcohols, ketones, esters, or the mixture thereof; isopropyl alcohol, acetone, ethanol, ethyl acetate, tetrahydrofuran or the mixture thereof is more preferred for the recrystallization of SHR1258 dimaleate.
  • the solvent for crystallization can be a single solvent or a mixture solvent comprising the solvents mentioned above.
  • the process for the preparation of form I crystal of SHR1258 dimaleate comprises the following steps:
  • the organic solvent in step 1 is selected from one or more solvent of alcohols with no more than three carbons, acetone, ethyl esters, tetrahydrofuran, preferably ethanol, isopropyl alcohol, tetrahydrofuran.
  • the most preferred single solvent is isopropyl alcohol.
  • the preferred mixture solvent is the mixture of ethanol and tetrahydrofuran.
  • the ratio of the two is not limited, while the volume ratio of 1:1 is preferred in an embodiment of the present invention.
  • the recrystallization method is not limited and can be performed with conventional recrystallization process in the art, for example, it may be that the SHR1258 dimaleate is heated to dissolve in organic solvent, and then the solution is cooled gradually to stand to crystallize or the solution is stirred to crystallize; after crystallization the resulting precipitate is collected by filtration and then dried.
  • a full conversion process is necessary for the formation of the stable crystal form, and amorphous structure or crystals with lower purity will form easily when the crystallization process is too fast which is usually caused by the supersaturation solution.
  • the increase in solvent volume or the decrease in crystallization rate will be helpful for the formation of a stable crystal form with high purity.
  • the crystal obtained by filtration is usually dried in vacuum at about 30 ⁇ 100°C, preferred 40 ⁇ 60°C, to remove recrystallization solvent.
  • the resulting crystal form of SHR1258 dimaleate was determined by DSC and X-ray diffraction patterns. Meanwhile, the residual solvent was also determined.
  • the crystal of SHR1258 dimaleate prepared according to the present method has no or very little residual solvent, which meets the requirement of the national pharmacopoeia for the residual solvent of drug products.
  • the crystal of the present invention can be properly used as pharmaceutical active ingredient.
  • the research results show that, the stability of the form I crystal of SHR1258 dimaleate obtained in the present invention is significantly better than the amorphous form under the condition of high temperature and high humidity. Moreover, the form I crystal has good stability under the condition of grinding, pressure and heating which can meet the production, transportation and storage requirements of medicaments.
  • the preparation process is stable and repeatable, which is especially suitable for the industrial production.
  • X-ray diffraction pattern is shown in figure 1 in which there are characteristic peaks at 6.28 (14.06), 6.74(13.10),10.60(8.34), 11.58(7.64), 13.50(6.55), 14.90(5.94), 15.80(5.60), 18.26 (4.85), 20.66 (4.30), 21.14 (4.20), 22.96(3.87), 24.34 (3.65), 25.54 (3.49), 26.12 (3.41).
  • DSC pattern is shown in figure 2 , with sharp molten absorption peak at 131.429°C. The crystal was defined as form I crystal.
  • the form I crystal of SHR1258 dimaleate and the amorphous form of SHR1258 dimaleate were placed opening in the air in various conditions including illumination, heating and humility.
  • the results show that the stability of the form 1 crystal of SHR1258 dimaleate and amorphous form of SHR1258 dimaleate are similar under the light without statistically significant.
  • the form I crystal of SHR1258 dimaleate is more stable than amorphous SHR1258 dimaleate under high temperate and high moisture condition.
  • Form I DSC peak 130.716°C
  • S0915100402H Heating at 80°C for 3 hours 1.0g of form I crystal of SHR1258 dimaleate was spread and heated at 80°C for 3 hours
  • Form I DSC peak 131.726°C

Abstract

Provided are crystalline Form I of (R,E)-N-(4-(3-chloro-4-(pyridin-2-yl -methoxy)-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl)-3-(1-methylpyrr olidin-2-yl) propenamide dimaleate (called SHR1258 dimaleate for short), preparation methods thereof and pharmaceutical composition containing the same. Said crystalline Form I of SHR1258 dimaleate has good crystal stability and chemical stability, and can be used in preparation of medicaments for treating diseases relevant to EGFR receptor tyrosine kinase or HER-2 receptor tyrosine kinase.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a crystalline form of dimaleate of tyrosine kinase inhibitors, particularly relates to form I crystal of (R, E)-N-(4-(3-chloro-4-(pyridin-2-yl-methoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6 -yl)-3-(1-methylpyrrolidino-2-yl)acrylamide dimaleate and the preparation and use thereof.
  • BACKGROUND OF THE INVENTION
  • In recent years, the cancer mortality in our country was clearly on the rise. People's life and quality of life were threatened seriously with cancer. Thus, it is a challenging and significant subject to search new anticancer drugs with high effect and low toxicity in the life sciences nowadays. Receptor tyrosine kinase is a kind of transmembrane protein involved in signal transduction. It is shown that over 50% of the proto-oncogene and oncogene product have the tyrosine kinase activity, whose abnormal expression will cause tumorigenesis. Tyrosine kinase inhibitor has been approved to be on the market since 2001, which has become a new class of anticancer drugs with outperformance.
  • Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase family. The epidermal growth factor receptor pathway plays a very important role in the tumorigenesis and progression, which has become the main research subject and one of the developing targets in the field of cancer therapy. Such drugs which has been on the market now comprise erlotinib, gefitinib and lapatinib (Tykerb, GW572016), as well as neratinib which is in the clinical phase now. Patent WO2011029265 discloses the method for the preparation of the compound (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquino line-6-yl)-3-(1-methylpyrrolidino-2-yl)acrylamide (referred as SHR1258 below for convenience). This drug molecule has distinct advantage of pharmacokinetics and pharmacodynamics. Although patent WO2011029265 discloses the chemical structure and preparation method of compound SHR1258, but is silent to the condition of its salification. In Chinese patent application 201110062359.8 , the dimaleate of this compound (referred as SHR1258 dimaleate below) has been described, and its structure is as follows:
    Figure imgb0001
  • However, the inventors did not make further research for the polymorph and preparation method of SHR1258 dimaleate. As known for the person skilled in the art, the polymorph structure of the pharmaceutically active ingredient always affects the chemical stability of the drug. Different storage conditions and crystallization conditions may lead to the change in the polymorph structure of the compound, which is sometimes accompanied with other forms of polymorph. In general, amorphous drug product does not have regular crystal structure, which often has other defects such as poor product stability, smaller particle size, hard filtration, agglomerate easily, and poor liquidity. Thus, it is necessary to improve all aspects of the nature of the above product. It is need to search a new polymorph which has higher polymorph purity and better chemical stability.
  • SUMMARY OF THE INVENTION
  • The present invention is to provide a stable crystal form of SHR1258 dimaleate and the preparation method thereof.
  • The inventor has test a series of crystallization products of SHR1258 dimaleate obtained under various conditions by X-ray diffraction and DSC test. The results prove that a stable crystal form of SHR1258 dimaleate which is referred as form I crystal can be obtained under normal crystallization condition. DSC patterns of the present form I crystal of SHR1258 dimaleate show distinct fusion absorption peak at 130°C. The X-ray diffraction pattern is shown in figure 1 which use Cu-Kα radiation to obtain the X-ray diffraction patterns represented by 2θ angels and interplannar crystal spacing (d value) in which there are characteristic peaks at 6.28(14.06), 6.74(13.10), 10.60(8.34), 11.58(7.64), 13.50(6.55), 14.90(5.94),15.80(5.60), 18.26(4.85), 20.66(4.30), 21.14(4.20), 22.96(3.87), 24.34(3.65), 25.54(3.49), 26.12(3.41).
  • In the method for the preparation of the crystal form I of the present invention, there is no special limitation for the existing form of SHR1258 dimaleate as starting material, and it can be used in any crystal form or amorphous form. The method for the preparation of form I crystal of SHR1258 dimaleate of the present invention comprises the following steps:
  • When use the low organic solvent, the polar organic solvent with fewer carbon atom and higher volatility which could be used as crystallization solvent is preferred, such as alcohols, ketones, esters, or the mixture thereof; isopropyl alcohol, acetone, ethanol, ethyl acetate, tetrahydrofuran or the mixture thereof is more preferred for the recrystallization of SHR1258 dimaleate. The solvent for crystallization can be a single solvent or a mixture solvent comprising the solvents mentioned above.
  • Specifically, the process for the preparation of form I crystal of SHR1258 dimaleate comprises the following steps:
    1. (1)The mixture of SHR1258 and maleic acid or the SHR1258 dimaleate solid is dissolved in q.s. of organic solvents, and the solution obtained is cooled to crystallization.
    2. (2) The crystal is filtered, washed and dried.
  • In a preferred embodiment of the present invention, the organic solvent in step 1 is selected from one or more solvent of alcohols with no more than three carbons, acetone, ethyl esters, tetrahydrofuran, preferably ethanol, isopropyl alcohol, tetrahydrofuran.
  • Furthermore, the most preferred single solvent is isopropyl alcohol.
  • In another embodiment of the present invention, the preferred mixture solvent is the mixture of ethanol and tetrahydrofuran. The ratio of the two is not limited, while the volume ratio of 1:1 is preferred in an embodiment of the present invention.
  • The recrystallization method is not limited and can be performed with conventional recrystallization process in the art, for example, it may be that the SHR1258 dimaleate is heated to dissolve in organic solvent, and then the solution is cooled gradually to stand to crystallize or the solution is stirred to crystallize; after crystallization the resulting precipitate is collected by filtration and then dried. In particular, a full conversion process is necessary for the formation of the stable crystal form, and amorphous structure or crystals with lower purity will form easily when the crystallization process is too fast which is usually caused by the supersaturation solution. The increase in solvent volume or the decrease in crystallization rate will be helpful for the formation of a stable crystal form with high purity. The crystal obtained by filtration is usually dried in vacuum at about 30∼100°C, preferred 40∼60°C, to remove recrystallization solvent.
  • The resulting crystal form of SHR1258 dimaleate was determined by DSC and X-ray diffraction patterns. Meanwhile, the residual solvent was also determined.
  • The crystal of SHR1258 dimaleate prepared according to the present method has no or very little residual solvent, which meets the requirement of the national pharmacopoeia for the residual solvent of drug products. Thus the crystal of the present invention can be properly used as pharmaceutical active ingredient.
  • The research results show that, the stability of the form I crystal of SHR1258 dimaleate obtained in the present invention is significantly better than the amorphous form under the condition of high temperature and high humidity. Moreover, the form I crystal has good stability under the condition of grinding, pressure and heating which can meet the production, transportation and storage requirements of medicaments. The preparation process is stable and repeatable, which is especially suitable for the industrial production.
  • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1 shows the X-ray powder diffraction pattern for the form I crystal of SHR1258 dimaleate.
    • Figure 2 shows the Differential Scanning Calorimetry pattern for the form I crystal of SHR1258 dimaleate.
    • Figure 3 shows the X-ray powder diffraction pattern for amorphous form of SHR1258 dimaleate.
    • Figure 4 shows the Differential Scanning Calorimetry pattern for amorphous form of SHR1258 dimaleate.
    DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is illustrated by the following examples in detail which in no way should be construed as limiting the scope of the present invention.
  • Experimental instruments 1, Thermal analysis (DSC)
    • Instrument type: Perkin-Elmer Pyris 1 Series Thermal Analysis System
    • Purging gas: Nitrogen
    • Heating rate: 10.0°C/min
    • Temperature range: 50-300°C
    • 2, X-ray diffraction spectrum
    • Instrument type: D/Max-RA Japan rigaku X-ray powder diffraction
    • Ray: monochromatic Cu- K rays (=1.5418 Å)
    • Scanning mode: /2 , Angular scan of 2-40°
    • Voltage: 40KV, Electric Current:40mA
    Example 1
  • 1.0g of SHR1258 (prepared according to patent WO2011029265 ) and 0.4g of maleic acid were dissolved in 25ml of isopropyl alcohol by heating. A solid was present while refluxing. After removing from heating, the obtained mixture was stirred to precipitate. The resulting precipitate was collected by filtration and then dried at 45 °C in vacuum overnight to obtain 0.85g of SHR1258 dimaleate crystal. Yield: 60%. X-ray diffraction pattern is shown in figure 1 in which there are characteristic peaks at 6.28 (14.06), 6.74(13.10),10.60(8.34), 11.58(7.64), 13.50(6.55), 14.90(5.94), 15.80(5.60), 18.26 (4.85), 20.66 (4.30), 21.14 (4.20), 22.96(3.87), 24.34 (3.65), 25.54 (3.49), 26.12 (3.41). DSC pattern is shown in figure 2, with sharp molten absorption peak at 131.429°C. The crystal was defined as form I crystal.
  • Example 2
  • 1.0g of SHR1258 and 0.4g of maleic acid were dissolved in 20ml of ethanol by heating. After removing from heating, the mixture was stirred overnight (the solid seperated was sticky). The next day, the mixture was added with 30ml of diethyl ether and stirred. The resulting precipitate was collected by filtration, washed with diethyl ether and then dried to obtain 1.03g of yellow solid. Yield: 73.5%. X-ray diffraction pattern of this solid is shown in figure 3 in which there are no characteristic peaks. DSC pattern is shown in figure 4, with no molten absorption peak below 170°C. It was determined that the product was amorphous form.
  • Example 3
  • 1.0g of SHR1258 dimaleate (prepared according to example 2) was added with 5ml of methanol and the mixture was heated to reflux until the solution obtained. The solvent was removed by evaporation in vacuum and 20ml of isopropyl alcohol was added. The solid was dissolved completely by heating and some solid presented while refluxing. After removing from heating, the mixture was laid to crystallization. The precipitate was collected by filtration and dried to obtain 0.80g solid. Yield: 80.0%. It was determined as form I crystal of SHR1258 dimaleate after comparing the X-ray diffraction patterns and DSC patterns.
  • Example 4
  • 2.0g of SHR1258 and 0.8g of maleic acid were heated to dissolve in 26ml of ethanol and tetrahydrofuran mixture (at a volume ratio of 1:1). The solution was stirred in 45°C water bath with solid seperated. After removing from heating, the mixture was stirred to crystallization. The precipitate was collected by filtration and dried at 45°C in vacuum overnight to obtain 2.3g of crystal. Yield: 82.0%. It was determined as form I crystal of SHR1258 dimaleate after comparing the X-ray diffraction patterns and DSC patterns.
  • Example 5
  • 1.0g of SHR1258 dimaleate solid (prepared according to example 2) was added in 5ml of water. The mixture was heated to reflux until the solution obtained. The solution was stirred to precipitate and sticky solid appeared the next day. The precipitate was collected by filtration and dried to obtain 0.68g solid. Yield: 68.3%. It was determined as the amorphous form of SHR1258 dimaleate from the X-ray diffraction patterns and DSC patterns.
  • Example 6
  • The form I crystal of SHR1258 dimaleate prepared in example 1 and the amorphous form of SHR1258 dimaleate prepared in example 2 were placed opening in the air to test the stability in various conditions including illumination (4500Lux), heating (60°C), humility (RH90%). The investigation duration is five and ten days and the HPLC analysis results are shown in table 1. Table 1. The comparing of stability of form I crystal and amorphous form crystal of SHR1258 dimaleate
    Bach number Solvent Time (Day) Light 60 °C RH90%
    Form I Crystal Isopropyl Alcohol 0 99.65% 99.65% 99.65%
    5 98.20% 98.13% 98.35%
    10 97.91% 96.86% 98.35%
    Amorphous Form
    95% Ethyl Alcohol 0 98.41% 98.41% 98.41%
    5 96.96% 95.24% 96.95%
    10 96.91% 93.71% 96.31%
  • The form I crystal of SHR1258 dimaleate and the amorphous form of SHR1258 dimaleate were placed opening in the air in various conditions including illumination, heating and humility. The results show that the stability of the form 1 crystal of SHR1258 dimaleate and amorphous form of SHR1258 dimaleate are similar under the light without statistically significant. The form I crystal of SHR1258 dimaleate is more stable than amorphous SHR1258 dimaleate under high temperate and high moisture condition.
  • Example 7
  • The form I crystal of SHR1258 dimaleate prepared in example 1 was grinded, heated and pressed, then judged by X-ray diffraction and DSC patterns. The results show that the crystal is stable and the data is shown in table 2. Table 2
    Batch number Process Experience process Crystal DSC
    Experiment 7.1 S0915100402G Grinding for 10 min 1.0g of form I crystal of SHR1258 dimaleate was grinded for 10min in mortar under nitrogen atmosphere. Form I DSC peak: 130.716°C
    Experiment 7.2 S0915100402H Heating at 80°C for 3 hours 1.0g of form I crystal of SHR1258 dimaleate was spread and heated at 80°C for 3 hours Form I DSC peak: 133.588 °C
    Experiment 7.3 S0915100402P Pressing Pressing the form I crystal of SHR1258 dimaleate into pieces Form I DSC peak: 131.726°C

Claims (7)

  1. Form I crystal of (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl) acrylamide dimaleate characterized in that using Cu-Kα radiation to obtain the X-ray diffraction patterns represented by 2θ angles and interplanar crystal spacing, the crystal has X-ray diffraction patterns as shown in figure 1 in which there are characteristic peaks at 6.28(14.06), 6.74(13.10), 10.60(8.34),11.58 (7.64),13.50(6.55), 14.90(5.94), 15.80(5.60), 18.26(4.85), 20.66(4.30),21.14(4.20),22.96(3.87),24.34(3.65),25.54(3.49),and 26.12(3.41).
  2. A method for the preparation of form I crystal of (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide dimaleate as claimed in claim 1 which comprises the following steps:
    1) The mixture of any crystal form or amorphous form of (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)-3-cyano-7-ethoxyquinolin-6 -yl)-3-(1-methylpyrrolidin-2-yl)acrylamide and maleic acid, or the solid of any crystal form or amorphous form of (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide dimaleate, is heated to dissolve in q.s. of organic solvent, then cooled to crystallization; said organic solvent is one or more of the solvent selected from the alcohol with no more than three carbons, acetone, ethyl acetate, tetrahydrofuran, preferably ethanol, isopropyl alcohol, tetrahydrofuran;
    2) The crystal was filtered, washed and dried.
  3. The method as claimed in claim 2, characterized in that the organic solvent in step 1) is isopropyl alcohol.
  4. The method as claimed in claim 2, characterized in that the organic solvent in step 1) is mixture solvent of ethanol and tetrahydrofuran.
  5. A pharmaceutical composition comprising form I crystal of (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide dimaleate according to claim 1 and pharmaceutically acceptable carrier.
  6. Use of form I crystal as claimed in claim 1 or pharmaceutical composition as claimed in claim 5 in the preparation of a medicament for the treatment of disease relevant to protein kinase, wherein said the protein kinase is chosen from EGFR protein tyrosine kinases or HER-2 receptor protein tyrosine kinases.
  7. Use of form I crystal as claimed in claim 1 or pharmaceutical composition as claimed in claim 5 in the preparation of a medicament for the treatment of cancer, wherein said cancer is lung cancer, breast cancer, epidermal squamous carcinoma or gastric cancer.
EP13817593.0A 2012-07-12 2013-06-04 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof Active EP2873664B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL13817593T PL2873664T3 (en) 2012-07-12 2013-06-04 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210240697.0A CN103539783A (en) 2012-07-12 2012-07-12 I-type crystal of dimaleate of tyrosine kinase inhibitor and preparation method thereof
PCT/CN2013/076717 WO2014008794A1 (en) 2012-07-12 2013-06-04 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof

Publications (3)

Publication Number Publication Date
EP2873664A1 true EP2873664A1 (en) 2015-05-20
EP2873664A4 EP2873664A4 (en) 2015-12-30
EP2873664B1 EP2873664B1 (en) 2017-11-01

Family

ID=49915377

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13817593.0A Active EP2873664B1 (en) 2012-07-12 2013-06-04 Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof

Country Status (21)

Country Link
US (1) US9309226B2 (en)
EP (1) EP2873664B1 (en)
JP (1) JP6170146B2 (en)
KR (1) KR102078077B1 (en)
CN (2) CN103539783A (en)
AU (1) AU2013289789B2 (en)
BR (1) BR112015000045B1 (en)
CA (1) CA2876884C (en)
DK (1) DK2873664T3 (en)
ES (1) ES2656623T3 (en)
HK (1) HK1199027A1 (en)
HU (1) HUE037946T2 (en)
MX (1) MX349672B (en)
NO (1) NO2873664T3 (en)
PL (1) PL2873664T3 (en)
PT (1) PT2873664T (en)
RU (1) RU2631321C2 (en)
TW (1) TWI597277B (en)
UA (1) UA113658C2 (en)
WO (1) WO2014008794A1 (en)
ZA (1) ZA201500471B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661405B2 (en) 2015-07-22 2023-05-30 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985408B (en) * 2015-02-12 2020-06-26 正大天晴药业集团股份有限公司 Purifying method of carfilzomib
MX2018008549A (en) * 2016-01-27 2018-09-19 Jiangsu Hengrui Medicine Co Pharmaceutical composition comprising quinoline derivative or salt thereof.
AU2017211737B2 (en) * 2016-01-27 2022-04-28 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
CN107708698A (en) * 2016-01-28 2018-02-16 江苏恒瑞医药股份有限公司 A kind of purposes of EGFR/HER2 receptor tyrosine kinase inhibitors in treatment HER2 mutation cancer drugs are prepared
CA3016092A1 (en) * 2016-03-22 2017-09-28 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Egfr inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application
CN113769097A (en) 2017-01-22 2021-12-10 江苏恒瑞医药股份有限公司 Use of EGFR/HER2 inhibitor in combination with pyrimidine antimetabolites
WO2019029477A1 (en) * 2017-08-07 2019-02-14 江苏恒瑞医药股份有限公司 Crystal form of dimaleate of tyrosine kinase inhibitor and preparation method therefor
CN109516976B (en) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 Crystal form of substituted pyrimidine PI3K inhibitor mesylate and preparation method thereof
TWI700086B (en) 2017-10-24 2020-08-01 大陸商江蘇恒瑞醫藥股份有限公司 Pharmaceutical composition containing quinoline derivative
CN110960529A (en) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 Tyrosine kinase inhibitor bulk drug with reduced toxic impurity content
US20210355109A1 (en) * 2018-10-22 2021-11-18 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of maleate of tyrosine kinase inhibitor and preparation method therefor
CN111138414A (en) * 2018-11-05 2020-05-12 江苏恒瑞医药股份有限公司 Crystal form of tyrosine kinase inhibitor and preparation method thereof
TW202115027A (en) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Tyrosine kinase inhibitor with low impurity content
CN114674937A (en) * 2020-12-24 2022-06-28 沈阳药科大学 Method for determining long-chain fatty amine in maleic acid long-chain fatty amide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
CZ20022332A3 (en) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101824029A (en) 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 Tyrosine kinase irreversible inhibitor and medicine composition and application thereof
CN102020639A (en) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-amido quinazoline or 3-cyano quinoline derivative, preparation method thereof and application of derivative to medicament
CN102675287A (en) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salts of (E)-N-(4-((3-chloro-4-(2-pyridyl methoxy) phenyl) amino)-3-cyano-7-ethyoxyl-6-quinolyl)-3-((2R)-1-methyl pyrrolidine-2-propyl)-2-acrylamide, preparation method and application of salts in medicines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661405B2 (en) 2015-07-22 2023-05-30 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions

Also Published As

Publication number Publication date
CN103974949B (en) 2015-11-25
JP6170146B2 (en) 2017-07-26
PL2873664T3 (en) 2018-06-29
HUE037946T2 (en) 2018-09-28
DK2873664T3 (en) 2018-01-08
CA2876884C (en) 2019-12-10
MX349672B (en) 2017-08-08
RU2015103065A (en) 2016-08-27
CN103974949A (en) 2014-08-06
KR20150036336A (en) 2015-04-07
BR112015000045B1 (en) 2021-10-26
CA2876884A1 (en) 2014-01-16
MX2014015623A (en) 2015-06-23
TWI597277B (en) 2017-09-01
EP2873664A4 (en) 2015-12-30
KR102078077B1 (en) 2020-02-17
AU2013289789A1 (en) 2015-01-22
ES2656623T3 (en) 2018-02-27
BR112015000045A2 (en) 2017-06-27
HK1199027A1 (en) 2015-06-19
WO2014008794A1 (en) 2014-01-16
PT2873664T (en) 2018-01-24
JP2015522042A (en) 2015-08-03
RU2631321C2 (en) 2017-09-21
CN103539783A (en) 2014-01-29
ZA201500471B (en) 2016-10-26
AU2013289789B2 (en) 2017-06-29
NO2873664T3 (en) 2018-03-31
EP2873664B1 (en) 2017-11-01
US20150166511A1 (en) 2015-06-18
US9309226B2 (en) 2016-04-12
TW201402563A (en) 2014-01-16
UA113658C2 (en) 2017-02-27

Similar Documents

Publication Publication Date Title
EP2873664B1 (en) Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
EP3216790B1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
US10118911B2 (en) P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
CN101774958B (en) I-type crystal of N-n-propyl-3-(4-methylphenyl)-4-(4-mesylphenyl)-2,5-dihydropyrrole-2-ketone and manufacturing method thereof
TW201815793A (en) Crystalline form of free alkali of imidazo isoindole derivative and a preparation method thereof
EP3348546B1 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
EP3202772A1 (en) L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound
CN104788435A (en) I-type crystal of dibenzenesulfonate of inhibitor of protein tyrosine kinase
TW201908320A (en) Crystalline form of btk kinase inhibitor and a preparation method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151201

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/14 20060101AFI20151125BHEP

Ipc: A61P 35/00 20060101ALI20151125BHEP

Ipc: A61K 31/4709 20060101ALI20151125BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170127

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170614

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JIANGSU HENGRUI MEDICINE CO., LTD.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170920

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 941881

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013028871

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180103

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2873664

Country of ref document: PT

Date of ref document: 20180124

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180117

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2656623

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180227

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Ref country code: NO

Ref legal event code: T2

Effective date: 20171101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 941881

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180301

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180201

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400067

Country of ref document: GR

Effective date: 20180518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013028871

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E037946

Country of ref document: HU

26N No opposition filed

Effective date: 20180802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20230523

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230517

Year of fee payment: 11

Ref country code: NO

Payment date: 20230524

Year of fee payment: 11

Ref country code: NL

Payment date: 20230525

Year of fee payment: 11

Ref country code: MC

Payment date: 20230523

Year of fee payment: 11

Ref country code: IT

Payment date: 20230608

Year of fee payment: 11

Ref country code: IE

Payment date: 20230519

Year of fee payment: 11

Ref country code: FR

Payment date: 20230630

Year of fee payment: 11

Ref country code: DK

Payment date: 20230531

Year of fee payment: 11

Ref country code: DE

Payment date: 20230613

Year of fee payment: 11

Ref country code: CZ

Payment date: 20230524

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230523

Year of fee payment: 11

Ref country code: SE

Payment date: 20230626

Year of fee payment: 11

Ref country code: PL

Payment date: 20230530

Year of fee payment: 11

Ref country code: HU

Payment date: 20230525

Year of fee payment: 11

Ref country code: GR

Payment date: 20230524

Year of fee payment: 11

Ref country code: FI

Payment date: 20230522

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230616

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230620

Year of fee payment: 11

Ref country code: ES

Payment date: 20230706

Year of fee payment: 11

Ref country code: CH

Payment date: 20230702

Year of fee payment: 11